论文部分内容阅读
目的:探讨头孢噻肟,头孢曲松等6种头孢菌素治疗儿童肺炎的成本-效果。方法:采用回顾性研究和成本-效果分析方法,对儿童肺炎成本进行药物经济学评价。结果:在达到基本一致(P>0.05)的治疗效果时,头孢噻肟、头孢曲松、头孢哌酮的成本及成本-效果较低,其余3种头孢菌素的这两项指标均有大幅提高。结论:与其他5种头孢菌素比较,用头孢曲松治疗儿童肺炎具有费用适中,成本-效果比及ADR发生率较低等优点。
Objective: To investigate the cost-effectiveness of 6 cephalosporins such as cefotaxime and ceftriaxone in children with pneumonia. METHODS: The pharmacoeconomic evaluation of children’s pneumonia costs was performed using retrospective studies and cost-effectiveness analysis. Results: The cost and cost-effectiveness of cefotaxime, ceftriaxone and cefoperazone were lower when the treatment effect was basically the same (P> 0.05). Both of the other three cephalosporins showed significant improve. CONCLUSIONS: Compared with the other 5 cephalosporins, the treatment of pneumonia in children with ceftriaxone has the advantages of moderate cost, cost-effectiveness ratio and low incidence of ADR.